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1. Introduction
Many studies of survival data involve mark variables that are only observed at an endpoint
event and it is of interest to investigate whether there is any relationship between the time to
endpoint and the mark variable. For example, in a clinical trial of drug regimens for treating HIV
infection, the time to treatment failure (typically dened by levels of viral load rising above a
threshold (Gilbert et al., 2001)) can decrease with increases in a distance measure describing the
extent of drug-selected HIV genetic evolution within a patient between baseline and the time of
failure. Detecting such an association can help in designing anti-HIV treatments that overcome
the problem of drug resistance, which represents one of the greatest barriers to achieving durably
eÆcacious treatment of HIV infection (Hirsch et al. 2000; Yeni et al. 2002).
In this article we develop tests for detecting whether a mark-specic hazard rate (or cumulative
incidence function) depends on the mark, and apply the tests to HIV genetic data collected in an
AIDS clinical trial. If we denote the time to endpoint T and the mark variable V , the observable
random variables are (X; Æ; ÆV ), where X = minfT;Cg, Æ = I(T  C), and C is a censoring
random variable that is assumed to be independent of T and V . When the failure time T is
observed, Æ = 1 and the mark V is also observed, whereas if T is censored, the mark is unknown.
Statistical interest focuses on the mark-specic hazard rate function
(t; v) = lim
h
1
;h
2
!0
PfT 2 [t; t+ h
1
); V 2 [v; v + h
2
)jT  tg=h
1
h
2
; (1)
and the cumulative incidence function
F (t; v) = lim
h
2
!0
PfT  t; V 2 [v; v + h
2
)g=h
2
; (2)
with t ranging over a xed interval [0;  ]. If V is discrete, the limit h
2
! 0 is not needed, and
the denitions (1) and (2) simplify respectively to the discrete cause-specic hazard function and
the discrete cumulative incidence function, which have received much attention in the competing
risks literature. In this article, the mark variable V is assumed to be continuous, in which case
the functions (1) and (2) are the natural analogs of their discrete counterparts, with similar
interpretations. In particular, (t; v) is the instantaneous risk of failure by a cause V in a small
interval [v; v + h
2
) in the presence of all other causes, and F (t; v) is the probability that failure
with V in a small interval [v; v + h
2
) will occur before the specied time t:
As with the classic competing risks model, the mark-specic hazard relates the cumulative
incidence function through the simple formula F (t; v) =
R
t
0
(s; v)S
T
(s) ds, where S
T
(t) is the
3
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survival function of T . Furthermore, just as the cause-specic hazard functions are the basic
estimable quantities when the mark variable is discrete (as originally pointed out by Prentice et
al., 1978), the mark-specic hazard function (1) is estimable from the available data and forms the
basis for inference when the mark variable is continuous. Indeed, the likelihood function under the
competing risks data with continuous mark has a similar form and is derived as follows. Assume
that the continuous mark variable V has a known bounded support; rescaling V if necessary, this
support is taken to be [0; 1]. Let f(t; v) be the joint density of (T; V ). Then (t; v) = f(t; v)=S
T
(t)
and (t) =
R
1
0
(t; v) dv is the overall hazard function of T . The likelihood function given n i.i.d.
observations (X
i
; Æ
i
; Æ
i
V
i
), i = 1; : : : ; n from the above model can be expressed in terms of the
mark-specic hazard rate as
Y
o
f(X
i
; V
i
)
Y
c
S
T
(X
i
) =
Y
o
(X
i
; V
i
)
n
Y
i=1
exp

 
Z
1
0
Z
X
i
0
(s; v) ds dv

; (3)
where
Q
o
denotes the product over the observed failure times,
Q
c
denotes the product over right
censored failure times, and each product only applies to the expression immediately in front.
These considerations motivate us to develop an inferential procedure based on the function (1).
Our interest centers on testing the null hypothesis
H
0
: (t; v) does not depend on v for t 2 [0;  ]
against the following alternative hypotheses:
H
1
: F (t; v
1
)  F (t; v
2
) for all v
1
 v
2
; t 2 [0;  ];
H
2
: (t; v
1
)  (t; v
2
) for all v
1
 v
2
; t 2 [0;  ];
H
3
: (t; v
1
) 6= (t; v
2
) for some v
1
 v
2
; t 2 [0;  ]
with strict inequalities for some t; v
1
; v
2
in both H
1
and H
2
. Equivalently, H
0
can be expressed
in terms of the cumulative incidence function F (t; v) not depending on v for t 2 [0;  ]: The null
hypothesis H
0
can also be written as H
0
: (t; v) = (t) for all t 2 [0;  ] and v 2 [0; 1]: Expressed
in this way, H
0
is the continuous version of the null hypothesis considered by Aly, Kochar, and
McKeague (1994), who developed a test for equality of two discrete cause-specic hazard rates,
H
0
: 
1
(t) = 
2
(t) for all t 2 [0;  ]:
As for the case of discrete competing risks, the interpretation of inferences on the mark-specic
hazard function (t; v) is restricted to actual study conditions (i.e., is \crude" or \gross"), and
there is no implication that the same inference would be made under a new set of conditions in
4
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which, for example, certain causes of failure v were not present. With T
v
denoting the latent
(i.e., notional) failure time for mark v (see Prentice et al., 1978, for discussion of latent failure
times), the assumption of mutual independence of the T
v
for all v 2 [0; 1] is needed for (t; v) to
possess the stronger interpretation as the hazard function for cause v given that all other causes
are inoperative. As in the discrete case, the independence assumption is untestable from the
available competing risks data (cf., Tsiatis, 1975); additional data such as observations of marks
beyond the rst failure time are needed. Thus, tests of H
0
have an interpretation in terms of
association, and cannot be used for causal inference of the predictive eect of a mark variable on
the risk of failure. The fact that the mark variable is only observed simultaneously with failure
makes clear the impossibility of causal inference (in the absence of strong untestable assumptions).
In the AIDS clinical trial example, V is a measure of the accumulated HIV genetic resistance
resulting from exposure to an antiretroviral treatment, which is measured only on subjects who
fail treatment, at the time of treatment failure. The test of H
0
versus the monotone alternative
H
1
(H
2
) assesses whether the absolute (instantaneous) risk of treatment failure increases with the
level of acquired drug resistance. If V is a reliable measure of the \resistance cost" of the regimen,
i.e., if the risk of treatment failure is higher for larger values of V , then we would expect to reject
H
0
in favor of H
2
: Thus, the test is useful for evaluating if V is a clinically relevant measure of
a treatment's resistance cost (see Gilbert et al. 2000 for a discussion of relevant resistance cost
metrics). Knowledge of clinically meaningful genetic resistance cost metrics would be helpful for
identifying combination drug regimens that do not select for drug resistant virus, and thus provide
long-lasting treatment eÆcacy.
A second example in which the proposed approach would be of interest is a prospective cohort
study of a population at risk for acquiring HIV infection. In this application, T is the time
from cohort entry until HIV infection, and V is the value of a metric measuring genotypic or
phenotypic dissimilarity of the HIV virus that infects a study participant from a reference HIV
strain. For example, V could be Hamming's genetic distance and the reference strain could be
the prototype virus contained in an HIV vaccine that is under development for eld testing in
the cohort population. The test of H
0
versus the two-sided hypothesis H
3
assesses whether the
HIV metric V is associated with the instantaneous risk of HIV infection. Finding evidence for
H
3
may suggest that the metric V can be used to guide selection of the types of HIV antigens
to include in HIV vaccines (Gilbert et al., 2001). For example, if H
0
is rejected and the infection
risk appears particularly high for v > 0:7, then it may behoove vaccine researchers to insert HIV
5
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antigens characterized by v > 0:7: Carrying out the test for multiple metrics in multiple genes
could help identify the metric(s) that optimize the breadth of expected protective coverage of
the vaccine. This application is important because the broad genotypic and phenotypic diversity
of HIV poses one of the greatest challenges to developing an eective AIDS vaccine (UNAIDS,
2001).
In the case of a discrete mark variable, tests for comparing mark-specic hazards can be found
in the literature on competing risks, see, e.g., Aly, Kochar, and McKeague (1994), Sun and Tiwari
(1995), Lam (1998), Hu and Tsai (1999), Luo and Turnbull (1999) and Sun (2001). Fine (1999)
developed a semiparametric regression method for competing risks data in which a discrete mark
V was used to stratify the eects of other covariates. This approach could not be used directly for
continuous marks because the subgroup with a given mark V = v would be empty or contain one
subject. Nevertheless, this work suggests that one may explicitly model the eect of continuous
mark V on the cumulative incidence function or mark-specic hazard rate. As mentioned earlier,
our testing procedure can be viewed as a continuous extension of the procedure of Aly, Kochar,
and McKeague (1994) and Sun (2001). To the best of our knowledge, however, these tests have
not been developed for continuous mark variables.
A nonparametric estimator of the joint distribution of a failure time and a failure mark which
may be continuous has been introduced by Huang and Louis (1998), with a view to applications
such as evaluating the relationship between a quality of life score and survival time (Olschewski
and Schumacher, 1990), or between lifetime medical cost and survival time. Their estimator
could be used to test whether T and V are independent by comparing it with the product of its
marginals. A test statistic based on this approach would have a complex asymptotic distribution,
however, and it is not clear that a tractable testing procedure could be formulated. Furthermore,
given the interpretability of the mark-specic hazard function in terms of the instantaneous risk
of failure, we argue that in some biomedical problems testing (t; v) independent of v is more
directly relevant than testing T and V independent. For example, for an HIV infected patient
receiving eective antiretroviral treatment at a given time, the risk of treatment failure over the
next month is of primary clinical interest, and is measured by the hazard function; accordingly
the relationship between the mark variable and the hazard function is of direct clinical interest.
In the case of nitely many causes of failure, test statistics can be based on dierences be-
tween Nelson{Aalen estimators of the cumulative cause-specic hazard functions, see Sun (2001).
Generalizing this approach, our test procedure is based on estimates of the doubly cumulative
6
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mark-specic hazard function (t; v) =
R
v
0
R
t
0
(s; u) ds du; estimation of this function was also
used in a fundamental way by Huang and Louis (1998). The idea of our testing procedure is
to compare a nonparametric estimate of (t; v) with an estimate under H
0
. We show that the
comparison can be weighted to make the test statistics asymptotically distribution-free.
This article is organized as follows. In Section 2 we introduce the test statistics and describe
a Monte Carlo procedure for approximating critical values. In Section 3 we derive the asymptotic
null distributions of the test statistics, and show that the Monte Carlo-derived critical values are
asymptotically accurate. The results of a simulation study and the AIDS clinical trial example
are presented in Sections 4 and 5, and proofs of results are given in the Appendix.
2. Test procedure
Given observation of i.i.d. replicates (X
i
; Æ
i
; Æ
i
V
i
); i = 1; : : : ; n of the (possibly right-censored)
marked failure times, a suitable nonparametric estimator of (t; v) is provided by the Nelson{
Aalen-type estimator
^
(t; v) =
Z
t
0
N(ds; v)
Y (s)
; t 2 [0;  ]; v 2 [0; 1]; (4)
where Y (t) =
P
n
i=1
I(X
i
 t) is the size of the risk set at time t, and
N(t; v) =
n
X
i=1
I(X
i
 t; Æ
i
= 1; V
i
 v)
is the marked counting process with jumps at the uncensored failure times X
i
and associated
marks V
i
, cf. Huang and Louis (1998, eq. 3.2). From (3), the log-likelihood can be expressed as
Z
1
0
Z

0
log (s; v)N(ds; dv)  
Z
1
0
Z

0
Y (s)(s; v) ds dv
and it follows by a routine extension of the argument of Andersen et al. (1993, p. 228) that
^
 is
the nonparametric maximum likelihood estimator of .
A closely related doubly cumulative hazard function estimator was introduced by McKeague
and Utikal (1990) and McKeague, Nikabadze, and Sun (1995), for testing independence of a
covariate from a failure time. The two estimators are not interchangeable, however, because
the covariate and the mark variable play dierent roles in each setting. The doubly cumulative
hazard function estimator of McKeague, Nikabadze, and Sun (1995) is formed by stratifying on
the covariate, which cannot be done on the mark for competing risks data since the mark is
not observed under censoring. The risk set at time t for the competing risks data cannot be
stratied by the marks since they are not available until the failures are observed. Although the
7
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current approach could be used to test for independence between a failure time and a covariate,
it would be more appropriate to use the test of McKeague, Nikabadze, and Sun (1995), leading
to a stronger conclusion when the null hypothesis is rejected. We also note here in passing that
it is important to distinguish a mark variable from a \marker"; the latter term is synonymous for
\covariate" in the survival analysis literature.
Because H
0
can be expressed as H
0
: (t; v) = (t) for all t 2 [0;  ] and v 2 [0; 1]; and
(t; v) = f(t; v)=S
T
(t), it follows that H
0
holds if and only if f(t; v) = f
T
(t) for all t and v, where
f
T
(t) is the density of T . Consequently, H
0
holds if and only if T and V are independent and V
is uniformly distributed over [0; 1]. Because of this fact, we can write (t; v) = v(t; 1); where
(; 1) is the cumulative hazard function of T under H
0
. Thus, under H
0
we can estimate the
doubly cumulative hazard function by

(t; v) = v
^
(t; 1).
2.1 Test processes and test statistics
We consider test processes of the form
L
n
(t; v) =
p
n
Z
t
0
H
n
(s) (
^
 

)(ds; v) (5)
for t  0; 0  v  1, where H
n
() is a suitable weight process. The weight process H
n
() provides a
exible way to specify the relative importance attached to dierences in the mark-specic hazards
at dierent times, and is useful for controlling instability in the tails. The bivariate test process
L
n
(t; v) is similar to the univariate test process L
n
(t) used by Aly, Kochar, and McKeague (1994,
p. 996) for comparing two competing risks 1 and 2; given by L
n
(t) =
R
t
0
w(s)d(
^

1
 
^

2
)(s); with
^

j
() the cause-j-specic Nelson-Aalen estimator.
Let y(t) = P (X  t) and ~ = supft: y(t) > 0g and assume  < ~ . We propose the following
test statistics to measure departures from H
0
in the direction of H
1
, H
2
and H
3
:
U
1
= sup
v
1
<v
2
sup
0t<
(t; v
1
; v
2
) (6)
U
2
= sup
v
1
<v
2
sup
0st<
((t; v
1
; v
2
) (s; v
1
; v
2
)) (7)
U
3
= sup
v
1
<v
2
sup
0t<
jL
n
(t; v
1
)  L
n
(t; v
2
)j (8)
where (t; v
1
; v
2
) = L
n
(t; v
1
) + L
n
(t; v
2
)  2L
n
(t; (v
1
+ v
2
)=2).
If the marks are discretized into K groups by stratifying the marks into K intervals of equal
length, the proposed tests reduce to the tests of Aly, Kochar, and McKeague (1994) for K = 2 and
are equivalent to the tests developed by Sun (2001). However, the tests using discrete marks could
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have nearly zero power to detect certain alternatives when the underlying marks are continuous.
This point will be discussed further following Theorem 3 on the omnibus property of the proposed
tests.
In the next section we show that L
n
(t; v) converges weakly to a Gaussian process under
H
0
. We also show that the proposed tests based on the U
j
are consistent against their respective
alternatives. Since each U
j
is a continuous functional of L
n
(t; v), its limiting null distribution is the
distribution of the corresponding functional of the limiting Gaussian process. These distributions
are intractable, however, so the critical values of the U
j
need to be determined using a simulation
procedure.
2.2 Monte Carlo procedure
The procedure is based on a randomized version U

j
of U
j
dened by replacing each V
i
by V

i
,
where V

1
; : : : ; V

n
are i.i.d. uniform [0,1] random variables. This yields a randomized version of
the test process given by
L

n
(t; v) =
p
n
Z
t
0
H
n
(s) (
^


(ds; v)  v
^


(ds; 1)); (9)
where
^


(t; v) =
R
t
0
N

(ds; v)=Y (s) and N

(t; v) =
P
n
i=1
I(X
i
 t; Æ
i
= 1; V

i
 v). Exploiting
the property that T and V are independent and V is uniformly distributed over [0; 1] under H
0
,
in Section 3 we show that the null distribution of U
j
coincides in the limit with the conditional
distribution of U

j
given the observed data. Therefore a critical value of U
j
can be approximated
via a Monte Carlo estimate of the quantile of U

j
corresponding to a given level of the test.
2.3 Choice of weight process and a graphical procedure
The simplest weight process, H
n
(t) = 1; yields a test process equal to a normalized dierence of
estimated doubly cumulative mark-specic hazard functions evaluated at v and at 1:
L
n
(t; v) =
p
n

^
(t; v)  v
^
(t; 1)

: (10)
This process is useful for a graphical procedure, in which the surface L
n
(t; v) is plotted together
with 10 or 20 realizations of the simulated null surface L

n
(t; v): Relative to the reference processes
L

n
(t; v); large values of curvature of L
n
(t; v) in v suggest H
1
; an increasing trend of this curvature
with time suggests H
2
; and absolute dierences in L
n
(t; v) over dierent mark values suggest H
3
:
The graphical procedure is illustrated in the example given in Section 5.
9
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To give the tests maximal power, the weight process should be chosen to downweight the
comparison of mark-specic hazards at larger times, where the test process is most variable. A
weight process that accomplishes this is given by H
n
(t) =
^
S
C
(t )
^
S
1=2
T
(t), where
^
S
C
and
^
S
T
are
the Kaplan{Meier estimators of S
C
and S
T
, respectively, S
C
being the survivor function of C.
As shown in the next section, this weight process has the added advantage of making the test
statistics asymptotically distribution-free.
3. Large-sample results
We begin by dening notation that is used in the sequel. Let (t; v) = P (X  t; Æ = 1; V  v).
By the Glivenko{Cantelli Theorem, N(t; v)=n and Y (t)=n converge almost surely to (t; v) and
y(t), uniformly in (t; v) 2 [0;1)  [0; 1] and t 2 [0;1), respectively. Let D(I) be the Skorohod
space for a k-dimensional rectangle I (Bickel and Wichura 1971), and C(I) be the subspace of
continuous functions on I. Also, let x^ y and x_ y denote the minimum and maximum of x and
y, respectively.
Our rst result describes the limiting null distribution of the test process.
Theorem 1
Let the weight process H
n
(t) be a continuous functional of the processes N(t; 1) and Y (t), t 2 [0;  ],
 < ~ . Assume there exists a measurable function H(t) such that sup
0t
jH
n
(t) H(t)j
a:s:
 !
0 and both H
n
and H have bounded variation independent of n almost surely. Then, under H
0
L
n
(t; v)
D
 !
Z
t
0
H(s)y(s)
 1
(G
1
(ds; v)  vG
1
(ds; 1))  L(t; v) (11)
in D([0;  ]  [0; 1]) as n ! 1, where G
1
(t; v) and G
2
(t) are continuous mean zero Gaussian
processes with covariances
Cov(G
1
(s; u); G
1
(t; v)) = (s ^ t; u ^ v)  (s; u)(t; v);
Cov(G
2
(s); G
2
(t)) = y(s _ t)  y(s)y(t);
Cov(G
1
(t; v); G
2
(s)) = ((t; v)   (s ; v))I(s  t)  (t; v)y(s):
The limiting process L(t; v) is a mean zero Gaussian process with covariance
Cov(L(s; u); L(t; v)) = (u ^ v   uv)
Z
s^t
0
H(r)
2
y(r)
2
(dr; 1): (12)
The process L(t; v) resembles the Kiefer{Muller process (van der Vaart and Wellner, 1996, p.
226).
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We next establish that the randomized version of the test process L

n
(t; v); introduced in
Section 2.2, has the same limiting null distribution as L
n
(t; v):
Theorem 2
Under the conditions of Theorem 1, conditional on the observed data sequence,
L

n
(t; v)
D
 !L(t; v) (13)
in D([0;  ] [0; 1]) under H
0
, where L(t; v) is given in Theorem 1.
Theorem 2 justies the Monte Carlo procedure described in Section 2.2, showing that it yields
asymptotically correct critical values of the tests. Furthermore, under mild conditions the tests
are consistent against their respective alternatives, as stated in Theorem 3.
Theorem 3
Suppose the conditions of Theorem 1 hold.
(a) If there exist (t
0
; v
1
; v
2
), 0 < t
0
<  , (v
1
; v
2
) 2 [0; 1], such that H
1
holds with strict inequality,
H(t)=S
T
(t) is decreasing and H(t
0
) > 0, then the test based on U
1
is consistent against H
1
.
(b) If there exist (t
0
; v
1
; v
2
), 0 < t
0
<  , (v
1
; v
2
) 2 [0; 1], such that H
2
holds with strict inequality,
H(t) and
R
v
0
(t; u) du are continuous in t in a neighborhood of t
0
, and H(t
0
) > 0, then the test
based on U
2
is consistent against H
2
.
(c) If (t; v) and (t) are continuous on [0;  ]  [0; 1] and [0;  ], respectively, and H(t)  c > 0
on [0;  ]; then the test based on U
3
is consistent against H
3
.
In practice, one may conveniently discretize the marks and apply the tests in Aly, Kochar,
and McKeague (1994) and Sun (2001). We caution that such procedures could have nearly
zero power to detect certain alternatives for the underlying continuous marks. For instance, if
the marks are grouped into two categories with V = 0:25 for those in the interval (0; 0:5) and
V = 0:75 for those in the interval (0:5; 1), then the test statistics U
1
, U
2
and U
3
reduce to the
tests of Aly, Kochar, and McKeague (1994). Let H
n
(t) = 1 and choose a model with continuous
mark such that
R
0:75
0:25
(t; u) du   0:5(t) = 0 for all t, but (t; v) 6= (t). This equation is
equivalent to
R
0:75
0:25
f(t; u) du   0:5f
T
(t) = 0 for all t, but f(t; v) 6= f
T
(t). A simple example of
such alternative is that f(t; v) = f
T
(t)f
V
(v) with f
V
(v) = 1   Æ + 4Æ(v   0:5) for v 2 (0:5; 1)
and f
V
(v) = 1   Æ   4Æ(v   0:5) for v 2 (0; 0:5), where 0  Æ  1. This alternative approaches
the null hypothesis as Æ ! 0. It follows from the proof of Lemma 1 that (ds; v)   v(ds; 1) =
11
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P (C  s)
R
v
0
f(s; u) du  vf
T
(s)

ds. By Proposition 2 in the Appendix, under such alternatives,
we have L
n
(t; 0:75)   L
n
(0:25)
D
 !
h
R
t
0
y(s)
 1
(G
1
(ds; v)  vG
1
(ds; 1))
i
v=0:75
v=0:25
, whose distribution
can be arbitrarily close to the corresponding null distribution with the uniform marginal for V as
Æ ! 0. This example shows that the test based on U
3
under discretized marks can have nearly
zero large-sample power for certain alternatives involving continuous marks. The same conclusion
can be reached for U
1
and U
2
.
We now show that the test statistics are asymptotically distribution-free when given the
weight process H
n
(t) =
^
S
C
(t )
^
S
1=2
T
(t) introduced in Section 2.3. Let
~
U
1
;
~
U
2
; and
~
U
3
denote the
test statistics with this weight process. With H(t) = S
C
(t )S
1=2
T
(t), simple calculation shows
that
R
t
0
H(s)
2
=y(s)
2
(ds; 1) =
R
t
0
f
T
(s) ds = F
T
(t). If ~ = supft:S
T
(t) > 0g, then, from the
previous discussion and by the continuous mapping theorem, under H
0
,
~
U
1
 sup
v
1
<v
2
sup
0t<~
(t; v
1
; v
2
)
D
 ! sup
v
1
<v
2
sup
0t<1
K(t; v
1
; v
2
)
~
U
2
 sup
v
1
<v
2
sup
0st<~
((t; v
1
; v
2
) (s; v
1
; v
2
))
D
 ! sup
v
1
<v
2
sup
0st<1
(K(t; v
1
; v
2
) K(s; v
1
; v
2
))
~
U
3
 sup
v
1
<v
2
sup
0t<~
jL
n
(t; v
2
)  L
n
(t; v
1
)j
D
 ! sup
v
1
<v
2
sup
0t<1
jK(t; v
2
) K(t; v
1
)j;
where (t; v
1
; v
2
) is dened following (8), K(t; v
1
; v
2
) = K(t; v
1
)+K(t; v
2
)  2K(t; (v
1
+ v
2
)=2);
and K(t; v) is a Kiefer process with Cov(K(s; u);K(t; v)) = (s^ t)(u^ v uv). Therefore, the
~
U
j
are asymptotically distribution-free test statistics. The asymptotic critical values of the tests
~
U
j
can be tabulated through a single simulation study based on the known properties of the Kiefer
process. This asymptotic distribution-free procedure, which applies only for the weight process
H
n
(t) =
^
S
C
(t )
^
S
1=2
T
(t), is computationally more eÆcient and provides a good alternative for
large sample sizes. However, the proposed Monte Carlo procedure can be used for a broad class
of weight processes, it provides more accurate critical values for moderate sample sizes, and it is
not overly cumbersome computationally.
Remark 1. In some applications, it is of interest to evaluate whether the instantaneous or absolute
risk of failure depends on a continuous mark variable in a given time interval, say [t
1
; t
2
); rather
than over the entire time range [0; ): The null and alternative hypotheses, and the test statistics
U
1
; U
2
; and U
3
, can be modied straightforwardly to address this problem. All of the results given
in this section carry over to this case, by replacing [0; ) everywhere with [t
1
; t
2
): In addition, the
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results continue to hold if the time range [0; ) is replaced with the possibly larger range [0; ~ );
see the remark following the proof of Theorem 2 in the Appendix.
4. Simulation results
We describe results of a simulation study of the test statistics
~
U
1
;
~
U
2
; and
~
U
3
:
First we consider a case with T and V independent. The cumulative incidence function is
then F (t; v) = PfT  tgf
V
(v), where f
V
is the density of V . We specify T to be exponential
with mean 1, and f
V
(v) = (1=)v
(1=) 1
for 0  v  1. Here  = 1:0 corresponds to the
null hypothesis H
0
and  = 0:75; 0:5; 0:25 correspond to three dierent alternative hypotheses
under the monotone alternatives H
1
and H
2
. The extent of departure from the null hypothesis
increases as  decreases. We also consider a two-sided alternative with f
V
(v) = 12(v   0:5)
2
,
0  v  1 (results in this case are given under the heading \two-sided" in Tables 1 and 2). Next,
we consider a case with T and V dependent. For the monotone alternatives H
1
and H
2
, we use
F (t; v) = PfT  tjV = vgf
V
(v) = (1   exp( t=(v + 1)))f
V
(v), with f
V
(v) = (1=)v
(1=) 1
for
0  v  1 and  = 0:5 and 0:25. For a two-sided alternative, we select V from uniform (0; 1) and
F (t; v) = 1  exp( v
4
t).
We choose n = 50; 100 and use a 30% censoring rate for the failure times. The sizes and powers
of the tests are calculated based on 1000 samples. The nominal level is set at 0.05 in each case.
The critical level for each test is calculated using 1000 independent replicates of fV

1
; : : : ; V

n
g.
The results in Table 1 indicate that the proposed tests perform well at moderate sample sizes.
The estimated sizes are all within 1.5% of the nominal 5.0% (range: 3.9% to 6.5%), and the
estimated powers are high for detecting  = 0:25 when n = 50 (range: 81.3% to 100.0%) and for
detecting  = 0:50 when n = 100 (range: 72.0% to 86.6%).
To this point, we have assumed that T and V are jointly continuous. In some applications,
however, some ties may be present in the data. To study the sensitivity of the tests to the presence
of ties, we use the same simulated data that yielded Table 1, and group the failure times into 25
tied values x
m
= 0:05 + 0:1(m   1) for 0:1(m  1) < x  0:1m, m = 1; : : : ; 24 and x
25
= 2:45 for
x > 2:4 (or x
m
= 3+6(m 1);m = 1; : : : ; 24; x
25
= 147 for the two-sided alternative model under
dependent T and V ), and group the failure marks into 20 tied values v
m
= 0:025 + 0:05(m   1)
for 0:05(m   1) < v  0:05m, m = 1; : : : ; 20: As mentioned earlier, this testing procedure for
the tied mark data is equivalent to the procedure of Sun (2001). The sizes and powers of the
tests for the grouped data at a 30% censoring rate and the 5.0% nominal level are given in Table
13
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2. We note that the presence of ties causes a slight but consistent decrease in the power of the
tests, and the levels become more conservative than in the untied case. The test based on
~
U
3
is
quite conservative for tied data, with estimated size 1.8% when n = 50: The test becomes less
conservative when the sample size is increased to n = 100; with estimated size 3.3%. An additional
simulation (not reported here) shows that, as might be expected, the tests have decreasing power
as the number of groups decreases.
The slightly larger sizes for n = 100 compared with n = 50 in Table 1 may be due to Monte
Carlo error: The reported sizes are the proportion of rejections of H
0
in 1000 samples, so they
have a Monte Carlo standard error of about [0:05  0:95=1000]
1=2
 100% = 0:7%.
PLACE TABLES 1-2 HERE
5. Application
In 1995 and 1996, the Adult AIDS Clinical Trials Group (AACTG) conducted a randomized trial
(Study 241) of 400 HIV infected adults to evaluate two combination antiretroviral treatments by
their ability to suppress HIV viral load (D'Aquila et al. 1996). The drug regimens contained
zidovudine and didanosine plus either nevirapine or nevirapine placebo. Gilbert et al. (2000)
analyzed the data from this trial with the failure time T dened as the time from randomization
until plasma HIV levels rose above 1000 copies/ml. The available genotypic data from the study
are the amino acids at 19 codons in the reverse transcriptase of HIV isolated from peripheral
blood mononuclear cells at baseline and at or after the time of failure from 12 patients on the
dual-drug arm and 33 patients on the triple-drug arm who failed. The 19 codons were chosen on
the basis of information from published studies that mutations in these positions confer resistance
to at least one of the studied drugs (Gunthard et al. 1999; Leigh-Brown et al. 1999; Hanna et
al. 2000). For the present analysis, codons with a resistance mutation are coded as ones while
codons with nonresistant (whether wildtype or variant) or ambiguous amino acids are coded as
zeros.
Let V
b
be the mutational distance of a subject's virus sequence measured at baseline relative
to the \wildtype" virus with no mutations, dened by
V
b
=
19
X
i=1
w
i
I(mutation at codon i)
,
19
X
i=1
w
i
;
where the weight w
i
measures the amount of resistance conferred by a mutation at the ith position,
as measured by a drug resistance assay. Dene V
f
similarly for a subject's virus sequence measured
14
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at or after the time of failure (we refer to this time as the \late week"). Then, we take V = V
f
 
2
3
V
b
as the measure of acquired mutational distance during the trial, which emphasizes new mutations
more than baseline mutations. The weights fw
i
g are taken to be those used by Gilbert et al.
(2000). Note that V is only dened and measured on subjects who fail treatment, and therefore
is appropriately viewed as a mark accompanying failure events rather than as a covariate. In
the analysis we consider both treatment arms in a single group. Pooling the arms is meaningful
because the accumulated resistance metric V is relevant for both arms, as they share the nucleoside
inhibitors zidovudine and didanosine.
PLACE FIGURES 1-3 HERE
As depicted in Figure 1, the mutational distance at baseline V
b
ranges between 0.0 and 0.187
in the 45 subjects who failed treatment, and increases to 0.0 to 0.435 by the late week, indicating
a trend of increase in mutational distance during the trial. The observed mark variable V takes
28 unique values for the 45 failures, ranging from 0.0 to 0.358, and appears to be approximately
uniformly distributed (Fig. 1c). A scatterplot of the mark versus failure time does not reveal
a systematic pattern (Fig. 2). To implement the tests, we rst normalize V by its maximum
observed value (0.358).
The tests conrm what is suspected from the descriptive plots, yielding nonsignicant results
for the three alternative hypotheses, with test statistics
~
U
1
= 0:628 (p = 0:59),
~
U
2
= 0:487
(p = 0:64); and
~
U
3
= 0:353 (p = 0:76): We next implement the graphical procedure, which uses
a unit weight process H
n
(t) = 1 in the test process L
n
(t; v) (as in (10)). When comparing the
surface L
n
(t; v) to eight simulated surfaces L

n
(t; v) (Fig. 3), they appear similar except that
L
n
(t; 0) rises above zero for increasing t while the processes L

n
(t; 0) tend to remain closer to zero.
Other than this caveat, which can be explained by the fact that four trial participants had a tied
mark value V = 0; the graphical comparison suggests that the observed test process does not
behave unusually compared to the behavior expected under the null hypothesis. We conclude
that there is no evidence that the instantaneous or absolute risk of virological failure depends on
the level of the resistance mutational distance variable V as dened above. Thus, V may not be
useful as a marker of drug resistance. It would be of interest to apply the testing procedure for
several other metrics V , as an exploratory search for marks that indicate drug resistance.
6. Concluding remarks
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The problem addressed here, evaluating whether there is a signicant association between the
instantaneous or absolute risk of failure and a continuous mark variable observed only at un-
censored failure times, has broad application. The two cited applications in AIDS research, in
which a time to disease or infection is measured and the mark describes a feature of the agent
that causes or is associated with the failure event, arises in many biomedical applications. For
one non-AIDS example, in studies evaluating survival of cancer patients, tumor mass might be
measured in patients at baseline and at the time of death, and the tests can be used to evaluate
a possible association between the growth rate of the tumor and the risk of death. In addition to
many other biomedical applications, including the aforementioned problems of assessing the rela-
tionship between the risk of death and a quality of life score or a lifetime medical cost, there are a
broad variety of applications in other scientic elds. Advantages of the tests developed here for
addressing these problems include that they are based on a nonparametric maximum likelihood
estimator which is a continuous generalization of the widely-applied and well-understood discrete
cause-specic Nelson{Aalen estimator, and they are asymptotically distribution-free.
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Appendix: Proofs of theorems
The following lemma is needed in the proofs of the main results.
Lemma
Assume that C is independent of (T; V ). Then
Z
t
0
(ds; v)
y(s)
=
Z
t
0
Z
v
0
(s; u) du ds (A.1)
Z
t
0
(ds; 1)
y(s)
=
Z
t
0
(s) ds: (A.2)
Proof: Let F
C
(t) be the distribution function of the censoring variable C. Recalling the
notation f(t; v) for the joint density of (T; V ), we have
(t; v) = P (T  t; T  C; V  v) =
Z
1
0
P (T  t; T  s; V  v) dF
C
(s)
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=Z
1
0

Z
s^t
0
Z
v
0
f(r; u) du dr

dF
C
(s) =
Z
t
0
Z
1
r
Z
v
0
f(r; u) du dF
C
(s) dr
=
Z
t
0
P (C  r)
Z
v
0
f(r; u) du dr:
It follows that
Z
t
0
(ds; v)
y(s)
=
Z
t
0

Z
v
0
f(s; u) du

P (T  s)

ds =
Z
t
0
Z
v
0
(s; u) du ds:
This proves (A.1). The result (A.2) follows by letting v = 1 and using
R
1
0
f(s; u) du = f
T
(s).
Proposition 1 describes the limiting distribution of the test process L
n
(t; v) when the weight
function is unity.
Proposition 1
For  < ~ ,
p
n(
^
(t; v) 

(t; v))  
p
n

(t; v)   v
Z
t
0
(s) ds

(A.3)
D
 !
Z
t
0
y(s)
 1
(G
1
(ds; v)   vG
1
(ds; 1))  
Z
t
0
G
2
(s)y(s)
2
((ds; v)   v(ds; 1))
in D([0;  ] [0; 1]).
Proof: By the empirical central limit theorem
p
n(N(t; v)=n   (t; v); Y (t)=n  y(t))
D
 !(G
1
(t; v); G
2
(t)) (A.4)
inD([0;  ][0; 1])D[0;  ], where G
1
(t; v) and G
2
(t) are continuous mean zero Gaussian processes
with covariances given in Theorem 1. Let D = D([0;  ]  [0; 1])  D[0;  ] be the product
space. The Nelson{Aalen-type estimator
^
(t; v) =
R
t
0
N(ds; v)=Y (s), 0  t   , depends on
the pair (n
 1
N(t; v); n
 1
Y (t)) through the following map from the domain of the type D

=
f(A(t; v); B(t)):
R
jA(dt; v)j M;B(t)  g  D for given M and  > 0:
: (A(t; v); B(t))  !
Z
t
0
1
B(s)
A(ds; v):
Let D
0
= C([0;  ]  [0; 1])  C[0;  ]. First, we show that the map  is Hadamard-dierentiable
tangentially to the set D
0
at every point (A;B) such that 1=B(t) is of bounded variation. Let t
n
!
0 be any converging sequences and let (
n
; 
n
)! (; ) 2 D
0
such that (A+t
n

n
; B+t
n

n
) 2 D

.
Then
t
 1
n
((A+ t
n

n
; B + t
n

n
)(t; v)   (A;B)(t; v))
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=Z
t
0
1
B(s) + t
n

n
(s)

n
(ds; v) 
Z
t
0

n
(s)
B(s)(B(s) + t
n

n
(s))
A(ds; v)
!
Z
t
0
1
B(s)
(ds; v)  
Z
t
0
(s)
B(s)
2
A(ds; v); uniformly in (t; v)
= 
0
A;B
(; )(t; v); (A.5)
where the limit is obtained by applying a lemma of Bilias, Gu, and Ying (1997). Let
Z
n
(t; v) =
p
n(
^
(t; v)  (t; v)): (A.6)
Since the pair (n
 1
N(t; v); n
 1
Y (t)), (t; v) 2 [0;  ]  [0; 1], is contained in the domain D

with
probability tending to 1 for M  1 and suÆciently small  > 0, applying the functional delta
method theorem (van der Vaart and Wellner, 1996, p. 374), (A.1) and (A.5), we have
Z
n
(t; v)
D
 !Z(t; v) ; (A.7)
where
Z(t; v) =
Z
t
0
1
y(s)
G
1
(ds; v)  
Z
t
0
G
2
(s)
y(s)
2
(ds; v): (A.8)
Now, consider the following continuous map from D([0;  ]  [0; 1]) into itself,
 
1
:  
1
(g)(t; v) = g(t; v)   vg(t; 1); (t; v) 2 [0;  ] [0; 1]: (A.9)
Applying the continuous mapping theorem, we get
Z
n
(t; v)   vZ
n
(t; 1)
D
 !Z(t; v)  vZ(t; 1); : (A.10)
Proposition 1 follows by plugging the specic forms (A.6) and (A.8) of the processes Z
n
and Z
into (A.10) .
Proposition 2 extends the result of Proposition 1 to general weight processes.
Proposition 2
Given the conditions expressed in Theorem 1,
L
n
(t; v)  
p
n

Z
t
0
Z
v
0
H
n
(s)(s; u) du ds   v
Z
t
0
H
n
(s)(s) ds

(A.11)
D
 !
Z
t
0
H(s)y(s)
 1
(G
1
(ds; v)   vG
1
(ds; 1))  
Z
t
0
H(s)G
2
(s)y(s)
2
((ds; v)   v(ds; 1))
in D([0;  ] [0; 1]).
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Proof: By the almost sure representations theorem (Shorack and Wellner 1986, p. 47), there
exist
~
N(t; v),
~
Y (t),
~
G
1
(t; v) and
~
G
2
(t) on some probability space such that
~
N(t; v),
~
Y (t),
~
G
1
(t; v)
and
~
G
2
(t) are equal in law to N(t; v), Y (t), G
1
(t; v) and G
2
(t), respectively, and (A.4) holds
almost surely uniformly in (t; v). Furthermore
~
N(t; v),
~
Y (t),
~
G
1
(t; v) and
~
G
2
(t) can be chosen
to have the same sample paths as the original processes. Let
~
Z
n
and
~
Z be the corresponding
representations of Z
n
and Z dened in (A.6) and (A.8), respectively. Repeating the steps of (A.5)
with t
n
= n
 1=2
, 
n
(t; v) =
p
n(N(t; v)=n  (t; v)) and 
n
(t) =
p
n(Y (t)=n  y(t)) and applying
the lemma of Bilias, Gu, and Ying (1997), we have
~
Z
n
(t; v)
a:s:
 !
~
Z(t; v); uniformly in (t; v) :
Consequently,
~
Z
n
(t; v)  v
~
Z
n
(t; 1)
a:s:
 !
~
Z(t; v)  v
~
Z(t; 1):
Let
~
H
n
(t) be the process H
n
(t) redened in terms of
~
N(t; v) and
~
Y (t). Then
~
H
n
(t) has the
properties of H
n
(t) assumed in the theorem. Applying the lemma of Bilias, Gu, and Ying (1997),
we have
Z
t
0
~
H
n
(s)(
~
Z
n
(ds; v)   v
~
Z
n
(ds; 1))
a:s:
 !
Z
t
0
H(s)(
~
Z(ds; v)   v
~
Z(ds; 1)):
Hence
Z
t
0
H
n
(s)(Z
n
(ds; v)   vZ
n
(ds; 1))
D
 !
Z
t
0
H(s)(Z(ds; v)   vZ(ds; 1)); (A.12)
in D([0;  ]  [0; 1]). Proposition 2 follows by plugging the specic forms (A.6) and (A.8) of the
processes Z
n
and Z into (A.12) and by (5).
Proof of Theorem 1: Under H
0
, the failure time T and the failure mark V are independent
and V is uniformly distributed on [0; 1]. Consequently, (t; v) = (t) for all (t; v). Further, since
the censoring variable C is independent of (T; V ), V is independent of (T;C) under H
0
. Hence,
(t; v) = v(t; 1) under H
0
. The result (11) follows by applying Proposition 2.
Let N
i
(t) = I(X
i
 t; Æ
i
= 1). By (A.4), under H
0
we have
n
 1=2
n
X
i=1
N
i
(t)(I(V
i
 v)  v))
D
 !G
1
(t; v)  vG
1
(t; 1)
in D([0;  ]  [0; 1]). Since H(t) and 1=y(t) are of bounded variation over t 2 [0;  ], the map
 
2
: g(t; v) !
R
t
0
H(s)y(s)
 1
g(ds; v); (t; v) 2 [0;  ]  [0; 1] from D([0;  ]  [0; 1]) into itself is
continuous on C([0;  ]  [0; 1]). Hence, by the continuous mapping theorem,
n
 1=2
n
X
i=1
(I(V
i
 v)  v))
Z
t
0
H(s)
y(s)
N
i
(ds)
D
 !
Z
t
0
H(s)
y(s)
(G
1
(ds; v)   vG
1
(ds; 1)) = L(t; v):
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The covariance of L(t; v) is given by, under the independence between V and (X; Æ),
Cov(L(s; u); L(t; v)) = Ef(I(V
i
 u)  u))(I(V
i
 v)  v))gE

Z
s
0
H(r)
y(r)
N
i
(dr)
Z
t
0
H(r)
y(r)
N
i
(dr)

= (u ^ v   uv)
Z
s^t
0
H
2
(r)
y(r)
2
(dr; 1):
Remark 2. An alternative (and more elegant) proof of Theorem 1 could be developed using
empirical process techniques. This would involve an extension to
^
 of Pollard's (1990, Section
13) derivation of the limiting distribution of the Nelson{Aalen estimator.
Proof of Theorem 2: Let L

1
(t; v) =
p
n(
^


(t; v) v
^


(t; 1)). Then L

n
(t; v) =
R
t
0
H
n
(s)L

1
(ds; v).
Let L
1
(t; v) =
R
t
0
y(s)
 1
(G
1
(ds; v)  vG
1
(ds; 1)). It is suÆcient to show L

1
D
 !L
1
conditionally in
D([0;  ]  [0; 1]).
Let N
i
(t) = I(X
i
 t; Æ
i
= 1) and N(t) =
P
n
i=1
N
i
(t). Then
L

1
(t; v) =
p
n
n
X
i=1
(I(V

i
 v)  v)
Z
t
0
dN
i
(s)
Y (s)
: (A.13)
To establish the conditional weak convergence of L

1
(t; v), we shall show that the nite dimensional
distributions of L

1
(t; v) converge weakly to those of L
1
(t; v) given the data sequence, and that
L

1
(t; v) is asymptotically tight given the data sequence; see van der Vaart and Wellner (1996, p.
183). The former task can be done by a simple application of the central limit theorem. The
asymptotic tightness of L

1
(t; v) given the data sequence can be proved by applying the tightness
criteria of Bickel and Wichura (1971, eq. 3, p. 1658) based on neighboring blocks. The details
are contained in a technical report that can be requested from the authors.
Proof of Theorem 3:
(a) Let
m(t; v) =
Z
t
0
Z
v
0
H
n
(s)(s; u) du ds   v
Z
t
0
H
n
(s)(s) ds:
Denote the left and the right side of (A.11) by L
a
n
(t; v) and L
a
(t; v), respectively. Then
U
1
= sup
v
1
<v
2
sup
0t<
(t; v
1
; v
2
)
= sup
v
1
<v
2
sup
0t<
[(L
a
n
(t; v
1
) + L
a
n
(t; v
2
)  2L
a
n
(t; (v
1
+ v
2
)=2))
+
p
n(m(t; v
1
) +m(t; v
2
)  2m(t; (v
1
+ v
2
)=2))]

p
n sup
v
1
<v
2
sup
0t<
((m(t; v
1
) +m(t; v
2
)  2m(t; (v
1
+ v
2
)=2)))
  sup
v
1
<v
2
sup
0t<
[ (L
a
n
(t; v
1
) + L
a
n
(t; v
2
)  2L
a
n
(t; (v
1
+ v
2
)=2))] (A.14)
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Note that
m(t; v
1
) +m(t; v
2
)  2m(t; (v
1
+ v
2
)=2)
a:s:
 !
Z
t
0
H(s)

Z
v
1
0
(s; u) du +
Z
v
2
0
(s; u) du  2
Z
(v
1
+v
2
)=2
0
(s; u) du

ds
=
Z
t
0
[H(s)=S
T
(s)] d

Z
v
1
0
F (s; u) du +
Z
v
2
0
F (s; u) du  2
Z
(v
1
+v
2
)=2
0
F (s; u) du

= [H(t)=S
T
(t)]

Z
v
1
0
F (t; u) du +
Z
v
2
0
F (t; u) du   2
Z
(v
1
+v
2
)=2
0
F (t; u) du

 
Z
t
0

Z
v
1
0
F (s; u) du +
Z
v
2
0
F (s; u) du  2
Z
(v
1
+v
2
)=2
0
F (s; u) du

d(H(s)=S
T
(s))
 [H(t)=S
T
(t)]

Z
v
1
0
F (t; u) du +
Z
v
2
0
F (t; u) du   2
Z
(v
1
+v
2
)=2
0
F (t; u) du

;
where the last inequality is obtained since
R
v
1
0
F (s; u) du+
R
v
2
0
F (s; u) du  2
R
(v
1
+v
2
)=2
0
F (s; u) du
 0 under H
1
and H(s)=S
T
(s) is decreasing. Under H
1
with the given t
0
such that the inequality
of the alternative H
1
holds strictly for some (v
1
; v
2
) 2 [0; 1],
R
v
0
F (t
0
; u) du is a strictly concave
function. Hence
Z
v
1
0
F (t
0
; u) du+
Z
v
2
0
F (t
0
; u) du  2
Z
(v
1
+v
2
)=2
0
F (t
0
; u) du > 0;
for some v
1
; v
2
2 [0; 1]. By Proposition 2, the second term of (A.14) converges in distribution
to a nite random variable. This yields U
1
P
 !1. Since U

1
converges in distribution to a nite
random variable, U
1
is consistent against H
1
.
(b) Note that, for s < t,
m(t; v
1
) +m(t; v
2
)  2m(t; (v
1
+ v
2
)=2)  m(s; v
1
) +m(s; v
2
)  2m(s; (v
1
+ v
2
)=2)
a:s:
 !
Z
t
s
H(r)

Z
v
1
0
(r; u) du +
Z
v
2
0
(r; u) du   2
Z
(v
1
+v
2
)=2
0
(r; u) du

dr:
Under H
2
, with the given t
0
such that the inequality of the alternative H
2
holds strictly for some
(v
1
; v
2
) 2 [0; 1],
R
v
0
(t
0
; u) du is a strictly concave function. Hence
Z
v
1
0
(t
0
; u) du+
Z
v
2
0
(t
0
; u) du  2
Z
(v
1
+v
2
)=2
0
(t
0
; u) du > 0;
for some v
1
; v
2
2 [0; 1]. Following a similar argument as in part (a) of the proof for the consistency
of U
1
, applying Proposition 2, and by the continuity assumptions of the theorem, we have U
2
P
 !1.
Since U

2
converges in distribution to a nite random variable, U
2
is consistent against H
2
.
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(c) Note that the alternative H
3
that (t; v) does not depend on v for all t 2 [0;  ] is equivalent
to
R
t
0
H(s)

R
v
0
((s; u)   (s)) du

ds not depending on v for all t 2 [0;  ]. Thus, under H
3
there
exists (t
0
; v
1
; v
2
), t
0
2 [0;  ], (v
1
; v
2
) 2 [0; 1] such that
m(t
0
; v
2
) m(t
0
; v
1
)
a:s:
 !
Z
t
0
0
H(s)

Z
v
2
v
1
((s; u)  (s)) du

ds 6= 0: (A.15)
Since
U
3

p
n sup
v
1
<v
2
sup
0t<
jm(t; v
2
) m(t; v
1
)j
  sup
v
1
<v
2
sup
0t<
j(L
n
(t; v
2
) 
p
nm(t; v
2
))  (L
n
(t; v
1
) 
p
nm(t; v
1
))j;
it follows by Proposition 2, the continuous mapping theorem and (A.15) that U
3
P
 !1 under H
3
.
Since U

3
converges in distribution to a nite random variable, U
3
is consistent against H
3
.
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Table 1. Observed levels and powers (%) of the test statistics
~
U
1
;
~
U
2
;
~
U
3
for testing H
0
versus
H
1
;H
2
;H
3
, respectively, at the 5.0% nominal level.
Independent T and V Dependent T and V
 
Size n Test 1 0.75 0.5 0.25 two-sided 0.5 0.25 two-sided
~
U
1
5.9 21.1 55.2 88.2 19.2 49.5 85.0 17.9
50
~
U
2
5.5 17.5 48.6 83.1 14.9 46.0 81.3 12.1
~
U
3
3.9 12.5 60.0 100.0 99.0 55.8 99.9 56.3
~
U
1
6.5 27.7 78.2 99.2 62.1 80.2 98.9 29.4
100
~
U
2
6.0 23.9 72.0 98.4 54.3 76.0 98.0 19.7
~
U
3
5.7 20.5 84.5 100.0 100.0 86.6 100.0 85.0
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Table 2. Observed levels and powers (%) of the test statistics
~
U
1
;
~
U
2
;
~
U
3
for testing H
0
versus
H
1
;H
2
;H
3
, respectively, with tied data at the 5.0% nominal level.
Independent T and V Dependent T and V
 
Size n Test 1 0.75 0.5 0.25 two-sided 0.5 0.25 two-sided
~
U
1
4.5 16.8 50.3 85.7 17.4 40.5 82.1 9.8
50
~
U
2
4.2 13.9 41.7 77.3 11.8 36.2 74.5 3.0
~
U
3
1.8 8.6 52.4 99.8 96.6 39.4 99.7 42.0
~
U
1
4.0 24.9 74.0 99.0 55.3 71.1 97.3 25.0
100
~
U
2
4.0 19.6 65.2 97.7 45.7 64.6 95.8 11.0
~
U
3
3.3 13.5 79.1 100.0 100.0 78.3 100.0 86.3
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FIGURE CAPTIONS
Figure 1. Genetic data from the 45 trial participants in AACTG Study 241 who failed antiretro-
viral therapy. The frequency distribution of the mutational distance is shown (i) at baseline (V
b
),
(ii) at the late week (V
f
), and (iii) accumulated between baseline and the late week (V = V
f
 
2
3
V
b
).
The mark V is the scaled weighted sum of indicators of zidovudine or didanosine resistance mu-
tations at positions 41, 65, 67, 69, 70, 74, 210, 215, and 219 in the reverse transcriptase gene, and
of the nevirapine resistance mutations at positions 98, 100, 101, 103, 106, 108, 179, 181, 188, and
190 in the reverse transcriptase gene. Details about the types of mutations, including the selected
weights based on the level of in vitro drug susceptibility, can be found in Gilbert et al. (2000).
Figure 2. Accumulated mutational distance V versus failure time, for the 45 subjects in clinical
trial AACTG Study 241 who failed antiretroviral therapy. The line in the plot is a lowess curve
that smooths the data in windows that contain two-thirds of the nearest data-points.
Figure 3. For clinical trial AACTG Study 241, for the testing procedures that account for ties
in the mark variable, (a) plots the test process L
n
(t; v); (b)-(i) plot individual realizations of the
simulated test processes L

n
(t; v):
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(ii) mutational distance at the late week
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(iii) mutational distance V accumulated during the trial
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